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Abstract
Malaria remains a major cause of mortality and morbidity worldwide. Progress
has been made in recent years with the development of vaccines that could
pave the way towards protection of hundreds of millions of exposed individuals.
Here we used a modular repertoire approach to re-analyze a publically
available microarray blood transcriptome dataset monitoring the response to
malaria vaccination. We report the seminal identification of interferon
signatures in the blood of subjects on days 1, 3 and 14 following administration
of the third dose of the RTS,S recombinant malaria vaccine. These signatures
at day 1 correlate with protection, and at days 3 and 14 to susceptibility to
subsequent challenge of study subjects with live parasites. In addition we
putatively link the decreased abundance of interferon-inducible transcripts
observed at days 3 and 14 post-vaccination with the elicitation of an
antigen-specific IgE response in a subset of vaccine recipients that failed to be
protected by the RTS,S vaccine. Furthermore, profiling of antigen-specific
levels of IgE in a Mozambican cohort of malaria-exposed children vaccinated
with RTS,S identified an association between elevated baseline IgE levels and
subsequent development of naturally acquired malaria infection during follow
up. Taken together these findings warrant further investigation of the role of
antigen-specific IgE in conferring susceptibility to malaria infection.
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            Amendments from Version 1
In response to reviewer comments we show in a new Figure 4 
the changes in abundance of FCER1 transcripts in the blood of 
vaccinated individuals. Furthermore, the overlap between the 
immunoprotesasome signature described by Vahey et al., 201015 
and the modular interferon signature reported in this paper has 
been assessed and the results are shown in Supplementary 
Figure S1. In addition, total and Plasmodium antigen specific 
IgE profiles were generated from plasma samples of subjects 
living in endemic areas who received the RTS,S vaccine. These 
results were obtained collaboratively and the six investigators who 
contributed to the work have been added as co-authors. Findings 
are shown in new Figure 5 and Figure 6, and Supplementary 
Figure S2–Supplementary Figure S3. Taken together these results 
do not show a direct relationship between levels of IgE elicited 
by the RTS,S vaccine protection in an endemic malaria disease 
setting. However, some of the findings show an association 
between elevated levels of IgE specific for Merozoite Surface 
Proteins and subsequent development of disease. The potential 
clinical relevance of these findings will have to be evaluated in 
independent cohorts of patients. Points of discussion have also 
been added based on these new results and comments from the 
reviewers. 
See referee reports
REVISED
Introduction
About 3.4 billion people, nearly half of the world’s popula-
tion, live in areas at risk of Plasmodium transmission1. Malaria 
infection resulted in an estimated range 149–303 million cases in 
2015 that may have caused between 236,000 and 635,000 deaths, 
according to the World Health Organization2. Recent concerns 
have been caused by the rise in parasite resistance to artemisinin, 
which is the last effective monotherapy available for the treatment 
of malaria3. Cases of artemisinin resistance have been reported 
from much of Southeast Asia and now appear likely to reach the 
Indian subcontinent, with potentially dire consequences4. However, 
significant advances over the past years have been made towards 
the development of an effective malaria vaccine5. Most notably this 
includes successful testing of a live vaccine consisting of radia-
tion-attenuated sporozoites6, and this year licensure by regulatory 
authorities of the first malaria vaccine, the recombinant adjuvanted 
vaccine developed by global pharmaceutical GSK, called RTS,S 
also known by its commercial name, Mosquirix®. This is a highly 
significant landmark but unfortunately the efficacy of the vaccine 
for unknown reasons, and despite optimization attempts, remains 
suboptimal7,8. Thus identification of mechanisms underlying pro-
tection conferred by this vaccine, or lack thereof, may be key to 
the development of a broadly effective prophylactic vaccine against 
malaria. Unbiased “systems approaches”, consisting in profiling 
all the elements constitutive of a given biological system, have 
recently been implemented to investigate responses to vaccines9. 
Such an approach consisting in measuring blood transcript abun-
dance on a genome-wide scale has been adopted for the serial pro-
filing of responses to the influenza, pneumococcal, yellow fever or 
malaria vaccines10–15. In 2010, Vahey et al. reported results from 
a study investigating changes in transcript abundance in blood 
following administration of the malaria RTS,S vaccine15. In this 
report we share the results of a re-analysis of the data made availa-
ble by Vahey et al. upon publication of their findings. We employed 
an approach which consists in identification of modular transcrip-
tional repertoires – collections of co-clustered gene sets – and 
subsequent modular-level “fingerprinting analyses”16. This re-
analysis led to original findings, with the identification of an 
interferon transcriptional signature at day 1 post-vaccination, cor-
relating with protection as well as a second interferon signature 
at days 3 and 14 post-vaccination correlating this time with lack 
of protection of study subjects from subsequent challenges with 
the malaria parasite. Downstream investigations identified a poten-
tial role for IgE responses of restricted specificity in mediating 
susceptibility to malaria infection.
Methods
Construction of the modular repertoire framework
The methodology for constructing modular transcriptional 
repertoires has been described earlier16,17. The particular framework 
employed in this re-analysis has been described in an earlier 
study investigating responses to influenza and pneumococcal 
vaccines12. Briefly, nine datasets were used as input, including 
blood transcriptome profiles generated from patients with HIV, 
tuberculosis, sepsis, systemic lupus erythematosus, systemic arthri-
tis, and liver transplant. Each dataset was clustered independently 
using Hartigan’s k-means clustering, using the elbow criterion to 
determine the optimal number of clusters for each dataset. Cluster 
membership information for each gene across the nine datasets was 
used to build a table recording the number of co-clustering events 
for each possible gene pair. This table was used in turn to build 
a weighted co-clustering network where each node is a gene and 
edges indicate co-clustering events with weight ranging from 1 
(pair of genes belonging to the same cluster in 1 out of 9 datasets) 
to 9 (pair of genes belonging to the same cluster in 9 out of 9 data-
sets). The module selection process consisted in the identification 
within this large network of cliques, which are densely connected 
subnetworks. A principled approach was used starting in the first 
round with the selection of the largest subnetworks carrying the 
highest weight (co-clustering in 9 out of 9 datasets; correspond-
ing to the M1 modules), followed by identification and removal 
from the selection pool of the next largest subnetwork and so on 
(with minimum clique size set at 10). When no additional mod-
ules could be identified for a given round of selection the strin-
gency of the selection criteria was progressively relaxed (e.g. 
co-clustering occurring for 8 out of 9 datasets in the second 
round of selection, corresponding to the M2 modules; in 7 out of 
9 datasets in the third round of selection, corresponding to the 
M3 modules, etc…). The datasets used for module construction 
have been deposited in NCBI’s Gene Expression Omnibus: 
GSE30101. These datasets span a broad range of pathologies, 
which are associated with inflammation, autoimmunity, infec-
tion, cancer, genetic defects of immunity or transplantation, thus 
allowing the capture of a broad repertoire of immune processes 
occurring in vivo.
Functional characterization of the blood modular repertoire
Functional analyses were carried out systematically for each 
module using commercial as well as publically available tools 
(primarily MetaCore™ version 5.0 and DAVID version 6.718) and 
results are reported on a wiki page: http://www.biir.net/public_
wikis/module_annotation/V2_Trial_8_Modules. A complete list of 
the genes forming the modules is also available from the wiki.
Page 3 of 23
F1000Research 2017, 4:919 Last updated: 18 JUL 2017
Module-level analyses
The top six rounds of modules defined by this approach (M1–M6, 
a total of 62 modules) were used as a framework to analyze and 
interpret the datasets generated in the context of the Vahey et al. 
study: i.e. rather than carrying out analyses at the individual gene 
level, which assume that changes in transcript abundance for each 
gene occur independently from that of other genes, we performed 
analyses at the modular level, where changes are assessed for sets 
of co-clustered genes. Thus we summarize “modular response” as a 
single value, the percent of responsive genes for a given module. In 
earlier analyses the average fold change per module was also used 
to demonstrate that high level of concordance could be observed 
across microarray platforms at the modular level but not at the 
gene level17. For determining changes for individual subjects post- 
vaccination a cutoff is set against which individual genes consti-
tutive of a module are tested. If the gene meets the set criteria it 
is considered “responsive”. “Module-level” data is subsequently 
expressed as a % value representing the proportion of responsive 
transcripts for a given module.
Serum sample for IgE detection. IgE levels were measured 
in serum samples obtained from subjects enrolled in a Phase 
IIb randomized controlled trial of the RTS,S/AS02 vaccine 
(ClinicalTrials.gov registry number NCT00197041) previ-
ously described by Alonso PL., et al19–21. Mozambican children 
between 1 and 4 years of age received either the adjuvanted 
RTS,S vaccine or a comparator vaccine (Hepatitis B vaccines in 
children older than 24 months; Pneumoccocal and Haemophilus 
vaccines in younger children). Briefly, blood samples were col-
lected at baseline from children before receiving the vaccine 
(pre-vaccination) and 1 month after 3rd dose of vaccination 
(post-vaccination). The children who developed malaria infec-
tion during follow up were designated as “Non-protected” and 
those who did not develop infection were designated as “Pro-
tected/ Non exposed”. Cohort 1: “Non-protected” were defined as 
children who had an episode of clinical malaria determined by 
passive case detection. That means that only sick children going 
to a health center with malaria diagnosed by blood smear were 
considered “Non-protected”. “Protected/ Non exposed” were chil-
dren who did not have any malaria episode during follow up, but 
they could have had an infection but did not go to a health post. 
Cohort 2: “Non-protected” were defined as children who had 
a P. falciparum infection determined by passive and active case 
detection. The difference with the cohort 1 was that every 15 days 
for the first 2.5 months and monthly after that, subjects had vis-
its at home to check temperature and if they had any fever then 
a slide and filter paper for PCR to detect parasitemia were done. 
Therefore, in this cohort it was more unlikely if a child had an 
infection that it would go unnoticed. “Protected/ Non exposed” 
were children who did not have any P. falciparum infection 
during follow up. Cohort 1 was from a medium transmission 
intensity area whereas Cohort 2 was from a high transmission 
intensity area. The study was approved by the Mozambican 
National Health and Bioethics Committee (Ref. 237/CNBS), 
the Hospital Clínic of Barcelona Ethics Committee (Registro 
2008/4444), and the PATH Research Ethics Committee (Study 
file number HS 482) and written informed consent was gathered 
from parents/guardians19,20.
IgE multiplex assay. Total and antigen-specific IgE levels were 
measured using a suspension array technology. Serum samples of 
23 children who received comparator vaccines (11 Non-protected 
and 12 Protected/Non-exposed subjects) and 44 children who 
received the RTS, S vaccine (22 Non-protected and 22 Protected/
Non-exposed subjects) were assessed in this assay, together with 
positive and negative controls. Each plate was designed balancing 
samples from both groups of vaccination, protection status, both 
cohorts, age and sex.
To measure total IgE levels, anti-human IgE-coupled beads (MAG-
Plex Beads, Luminex Corp.) were mixed with serum samples at 
1/50 dilution to capture total IgE. Biotinilated anti-human IgE fol-
lowed by streptavidin-phycoerythrin were added to detect IgE. An 
18 points-Standard curve starting at 2000 ng/ml of human IgE and 
finishing at 0.015 ng/ml was included as part of quality assurance/
quality control (QA/QC).
To measure RTS,S antigen-specific IgE levels, six Plasmodium fal-
ciparum antigens and one hepatitis B virus antigen were coupled to 
different bead populations to create a multiplex panel: circumspo-
rozoite surface protein (full length CSP, purchased from Sanaria), 
NANP repeat region of CSP and C-term part of CSP (obtained 
from Walter Reed Army Institute of Research - WRAIR, USA), 
MSP2 (from 3D7 strain, obtained from the Institute of Immunol-
ogy & Infection Research and Centre for Immunity, Infection & 
Evolution, University of Edinburgh, UK), MSP3 (from 3D7 strain, 
obtained from the International Centre for Genetic Engineering and 
Biotechnology, India), EXP1 (purchased from Sanaria) and hepa-
titis B surface antigen (HBsAg, purchased from Abcam). Because 
CSP NANP repeat, C-term fragments and MSP2 were expressed 
with a GST-Tag, a GST-coupled bead was also included. Briefly, 
antigen-coupled beads were mixed with serum samples at dilutions 
1/30, 1/270, 1/2,430 and 1/21,870 to capture antigen-specific IgE. 
Subsequently, mouse anti-human IgE and biotinilated goat anti-
mouse IgG were added as secondary and tertiary antibodies and 
finally streptavidin-phycoerythrin was added. Results are expressed 
in Median Fluorescence Intensity (MFI) and at least 50 beads per 
analyte/well were acquired in Luminex xMAP® 100/200 analyzer.
Statistical analyses
Mann Whitney tests were performed on individual module response 
values expressed as percentages comparing protected and non- 
protected groups. Wilcoxon signed-rank test were performed to 
compare response between pre-vaccination and post-vaccination 
using GraphPad Prism software version 6 (GraphPad Software, 
San Diego, CA).
Results
Study design and reanalysis using modular repertoires
The design of the vaccine trial is described in detail by Vahey 
et al. and in an earlier publication15,22. Briefly, study subjects 
received the RTS,S vaccine, which consists of sequences of the 
P. falciparum CSP expressed in hepatitis B surface antigen and 
formulated with the proprietary adjuvant systems AS01/AS0223. 
Challenge was performed with a homologous 3D7 strain of 
P. falciparum delivered by 5 bites from infected mosquitoes. 
Samples were obtained from study participants at study entry 
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(36 samples); on the day of the third vaccination (44 samples); 
at day 1 (43 samples), day 3 (43 samples), and day 14 (37 
samples) thereafter; and at day 5 post-challenge (39 samples). 
Peripheral blood mononuclear cells (PBMC) transcriptome 
profiles were generated using commercial Affymetrix HG-U133 
chips. Data processing and normalization methodologies are 
described in the original publication. Data are available publically 
from the NCBI Gene Expression Omnibus (GSE18323). Only the 
blood transcriptional profiles generated on the day of the third 
vaccination and at day 1, day 3 and day 14 post-third vaccination 
were used in our re-analysis.
We employed a “modular repertoire approach” first described in 
2008 in a research paper17, and more recently in a review16. Briefly, 
this approach consists in a priori identifying relationships among 
constituents of a given biological system, which in our case is the 
blood transcriptome. This makes it in turn possible to analyze tran-
scriptional profiles as functionally interpretable gene sets rather 
than independent genes. Modular repertoires are established in an 
entirely data-driven process through the recording of co-clustering 
patterns of transcripts across a wide range of immune-related dis-
eases. A collection of datasets encompassing infectious as well as 
autoimmune disorders and primary immune deficiency was used as 
input in order to capture a wide variety of immune signatures. The 
module construction process and modular analyses are described in 
detail in the Methods section.
In the original analysis of this dataset Vahey et al. report the iden-
tification: 1) of a transient signature at 24 hours post-vaccination 
that was not observed at subsequent time points. This signature is 
described as being associated with inflammatory processes elicited 
by the vaccine and was not associated with outcome of the infec-
tious challenge; 2) of a signature at 5 days post-challenge that dis-
tinguish vaccinated from non-vaccinated individuals, thus directly 
reflecting and demonstrating the effect of vaccination; 3) of a sig-
nature at 14 days post-vaccination correlating with protection con-
ferred by the vaccine. This 393-gene signature was identified using 
high resolution Gene Set Enrichment Analysis (GSEA) and con-
sisted in transcripts belonging to the immunoproteasome pathway 
associated with the processing of major histocompatibility complex 
class I peptides.
Increased interferon module response at day 1 correlates 
with protection
In our re-analysis we first assessed changes in transcript abundance 
at the modular level. The percentage of responsive transcripts con-
stitutive of a given module was determined for each individual at 
days 1, 3 and 14 following administration of the third vaccine dose 
in comparison to the levels obtained in samples collected just prior 
to that injection (see Methods for details). Hierarchical clustering 
was then performed at each time point to group modules (rows) 
and subjects (columns) based on patterns of changes in blood tran-
script abundance represented by the percent module response val-
ues (day 1, Figure 1A). Modules were filtered to only retain those 
with changes >15% in at least one subject. This arbitrary cutoff is 
set at three times the false discovery rate used for multiple testing 
correction (5%). This analysis is unsupervised since it does not take 
knowledge of outcome of the infectious challenge into account. 
We observed nonetheless that samples tended to segregate based 
on whether or not the vaccine conferred protection (Figure 1A). 
Three modules associated with induction by interferon appeared 
to be the main elements driving the clustering of study subjects, 
with higher abundance levels being observed in subjects protected 
from subsequent infectious challenge. We demonstrated in our 
previous work that those three interferon modules represent dis-
tinct signatures that can be used for stratification of subjects 
with systemic lupus erythematosus24. Thus, we used in turn the 
same M1.2, M3.4 and M5.12 modules to stratify malaria vaccine 
recipients. Hierarchical clustering using only this subset of 
modules contributed to further separation of subjects based on 
the outcome of the infectious challenge (Figure 1B). The differ-
ence in % module responsiveness between protected and non- 
protected subjects was also statistically significant for M1.2 
(p=0.0094, Mann Whitney test) (Figure 1C). M3.4 tended to be 
elevated compared to pre-vaccination baseline in both protected 
and non-protected individuals but was not different between 
those two groups. Abundance of M5.12 transcripts did not change 
following vaccination.
Decreased interferon module response at days 3 and 14 
correlate with lack of protection
We next used a similar approach to classify subjects at days 3 and 
14 post-third vaccination. Subjects once again segregated based on 
whether or not protection is conferred by the vaccine (Figures 2A 
& 2B). Notably, however, at these time points the signature showed 
a decrease in levels of transcript abundance in comparison to base-
line pre-vaccine samples in subjects that were not protected. Thus 
conversely with the signature described at day 1, signatures at days 
3 and 14 correlated with lack of protection by the vaccine. Differ-
ences between protected and non-protected groups where highly 
significant for M1.2 (Figure 2C, day 3 p<0.0001, day 14 p<0.0001, 
Mann Whitney test). M3.4 and M5.12 did not show significant dif-
ferences between those groups. Notably, we found that the genes 
constitutive of M1.2, M3.4 and M5.12 do not overlap with the day 
14 immunoproteasome signature (32 genes) described by Vahey 
et al (Supplementary figure 1). All but three of the 32 genes mapped 
to the modules constituting our repertoire. Six genes mapped to 
module M5.13 and three to module M5.4, the remaining 23 genes 
mapped to 18 other modules. However, none of the genes mapped 
to either of the three interferon modules identified as associated 
with protection by RTS,S vaccine at Day 1, 3 or 14 after the third 
vaccination. Notably, IFNG, which was part of the 32 gene signa-
ture is among the genes constituting M3.6, which is associated with 
NK cells/Cytotoxic activity. Taken together results of our reanalysis 
of the Vahey dataset using a modular repertoire framework led to an 
original finding, by demonstrating the association between diverg-
ing day 1 and days 3 and 14 interferon signatures and protection 
conferred by the RTS,S vaccine.
Putative model accounting for the contrasted interferon 
signatures observed in response to RTS,S vaccination
We have shown in an earlier work that the three interferon 
modules that were described above tend to become elevated 
sequentially in patients with systemic lupus and may be associ-
ated with differential induction of type I and type II interferon in 
this disease24. Furthermore, lupus disease severity was found to 
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Figure 1. Increased modular interferon response at day 1. Blood transcriptional responsiveness to malaria vaccination was determined 
at the modular level in subjects one day following administration of the third dose of RTS,S. A. The percentage of responsive transcripts 
was determined for each module (co-clustered gene set) and represented by a colored spot on a heatmap where modules are arranged in 
rows and samples in columns (using a custom web; manuscript describing this resource is in preparation). Increases in transcript abundance 
compared to baseline pre-third vaccine sample are shown in red and decreases in transcript abundance in blue. Modules and samples 
are arranged by hierarchical clustering based on patterns of module responsiveness. B. Grouping of samples based on patterns of 
responsiveness of interferon modules is shown here. C. Responsiveness of the three interferon modules on day 1 is shown on a plot.
correlate significantly with M5.12 levels. We have also shown that 
an interferon response dominated by M1.2 and M3.4 was tran-
siently increased 1 day following vaccination with the trivalent 
influenza virus12. O’Gorman et al. recently demonstrated that this 
transient interferon response is mediated by flu antigen-specific IgG 
immune complexes rather than engagement of pathogen-associated 
molecular pattern receptors25. The day 1 interferon response 
observed in the context of malaria vaccination could similarly be 
the result of engagement of CSP-specific IgG immune complexes 
since it occurs following administration of the third dose of RTS,S, 
at a time when a pre-existing humoral response would have been 
elicited by the first two doses.
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But most peculiar is the fact that this increased modular interferon 
response in protected individuals at day 1 is followed by a per-
sistent decrease in abundance of M1.2 transcripts below the pre- 
vaccination baseline in individuals who were not protected by the 
RTS,S vaccine. Indeed, in over 10 years of investigating blood tran-
scriptome responses in a wide range of clinical and experimental 
settings the authors have not encountered a single instance of such a 
sustained and uniform decrease in abundance of interferon-induci-
ble transcript. What is especially striking is the clear cut association 
between lack of protection conferred by RTS,S with the decrease in 
abundance of M1.2 transcripts seen in Figure 2C. This implies that 
the immunological mechanism underlying this suppressed inter-
feron signature may be key to overcoming current limitations of 
sub-unit malaria vaccination.
Figure  2.  Decreased  modular  interferon  response  at  days  3  and  14.  Blood transcriptional responsiveness to malaria vaccination 
was determined at the modular level in subjects 3 and 14 days following administration of the third dose of RTS,S. A. As is the case of 
Figure 1 the percentage of responsive transcripts was determined for each module (co-clustered gene set) and represented by a colored 
spot on a heatmap where modules are arranged in rows and samples in columns. Increases in transcript abundance compared to baseline 
pre-third vaccine sample are shown in red and decreases in transcript abundance in blue. Modules and samples are arranged by hierarchical 
clustering based on patterns of module responsiveness. B. Similar description as in A, this time applied to day 14 data. C. Responsiveness 
of module M1.2 at days 3 and 14 post vaccination are represented on a plot showing also differences between the protected and non-
protected groups.
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Here we putatively attribute this decrease in abundance of inter-
feron-inducible transcripts and subsequent lack of protection to the 
elicitation by the vaccine of an antigen-specific IgE response. This 
hypothesis is based on an array of converging evidence:
1)    Engagement of the high affinity IgE receptor, FCER1, 
mediates decreased responsiveness to interferon-inducing 
stimuli. Gill et al. have shown that plasmacytoid dendritic 
cells (pDCs) isolated from patients with allergic asthma 
produce reduced levels of interferon alpha in response to 
the influenza virus in vitro when compared with pDCs iso-
lated from non-asthmatic controls26. They also demonstrated 
Figure 3. Proposed immunological mechanism determining protection – or lack thereof – in adult human individuals to whom was 
inoculated the RTS,S vaccine. Our model infers that the interferon signatures observed on days 1, 3 and 14 post-vaccination correlating with 
outcome of the processes that deploy post the co-delivery of Anopheles saliva and P. falciparum sporozoites, are the result of engagement of 
Fc receptors by immune complexes. According to our model no interferon signatures should be observed following administration of the first 
vaccine dose of the CSP- containing RTS,S vaccine, in absence of pre-existing immune effectors/regulators reactive to P. falciparum Circum 
Sporozoite Protein/CSP. The injection of the first two doses of vaccines should elicit a humoral response, which in non-protected individuals is 
dominated by CSP- binding IgE rather than IgG. CSP- Ig- immune complexes should form when the third vaccine dose is administered. The 
transient interferon response elicited in individuals who develop a protective response and that we observed at Day 1 could be mediated by 
engagement of the FcγR by IgG-CSP immune complexes as has been described earlier in the context of influenza vaccination)25. Our model 
predicts that IgE-CSP complexes form in non-protected individuals and cross-link the high affinity IgE receptor at the surface of cells of the 
myeloid lineage. FCER1 engagement would in turn mediate reduction in levels of IFN-inducible transcripts that is observed on days 3 and 14. 
This reduction of constitutive levels of IFN-inducible transcripts in the non-protected group would be countered at least partially on Day 1 by 
residual IgG-IC response in subjects displaying mixed IgE/IgG humoral responses. If this is indeed the case the levels of M1.2 reduction on 
Day 1 in individuals displaying CSP-binding IgE should be inversely correlated with levels of CSP-specific IgG. Given the transient nature of 
the interferon signature that was observed and that we tentatively attribute to IgG ICs, this partial reversal of IgE mediated suppression would 
not be observed at later time point, which would account for the sustained decrease in abundance of interferon-inducible transcripts that 
was observed at days 3 and 14. Engagement and crosslinking of FCER1 may also result in altered phagocytic and parasite killing abilities33 
thus potentially contributing to diminished resistance to infection in cases where the humoral response to RTS,S vaccination is dominated by 
IgE.
that production of interferon alpha by pDC stimulated 
in vitro with the virus is significantly decreased upon 
cross-linking of the FCER1 receptor26. Similar findings 
have been reported more recently in PBMCs exposed to 
Human Rhinovirus (HRV)27. This is to our knowledge the 
only immune-mediated mechanisms of suppression of 
interferon responses that may explain the decrease in M1.2 
observed following RTS,S vaccination. Thus we hypoth-
esize that the suppression by RTS,S of levels of interferon 
inducible transcripts results from formation of IgE-CSP 
immune complexes, with anti-CSP IgE being elicited in 
earlier rounds of vaccination (Figure 3). An alternative 
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explanation is advanced by one of the reviewers, Dr Luty, in 
his comments, who mentions the potential relevance of the 
use of a 226 amino acid stretch of HBsAg as a conjugate for 
the CSP antigen in the RTS,S vaccine. Indeed this molecule 
has also been shown to inhibit Toll-like Receptor (TLR)9- 
mediated IFN-α production by pDC28. and “could thus 
potentially be exerting some influence on the outcome 
of immunization in term of the anti-malarial protection 
generated”29. This is indeed another possibility, which war-
rants testing of the inhibitory capacity of the protein fragment 
used in RTS,S vaccine formulation. Furthermore the cell 
populations and signaling pathways involved in elicitation 
and modulation of interferon responses by RTS,S vaccine 
would also need to be investigated. Indeed, as mentioned 
earlier it was found for instance that, rather unexpectedly, 
the induction of interferon response by the trivalent influ-
enza vaccine is mediated by IgG immune-complexes rather 
than TLR engagement25. We hypothesized that interferon 
signatures observed in response to RTS,S vaccination arise 
through a similar mechanism, which may be antagonized 
by IgE immune complexes.
2)    Further evidence pointing to the influence of IgE responses 
comes from the literature and from results of our prelimi-
nary investigation reported below showing a dependence 
on both pre-erythrocytic and blood stages and antigen 
specificity of IgE on outcomes of malaria infection in chil-
dren from endemic areas. Perlmann et al. identified IgE as 
a pathogenic factor in malaria, with immune complexes 
contributing to excess TNF induction in PBMC in vitro30. 
Mice deficient for the high affinity IgE receptor have shown 
increased resistance to blood-stage of parasite infection, 
specifically implicating FCER1 expressing neutrophils as 
pathogenic mediators31. A more recent study has established 
a link between asthma and atopic dermatitis and delayed 
development of clinical immunity to P. falciparum32. Nota-
bly, in addition to shifting cytokine balance by promoting 
IL-10 and TNF production, engagement of high affinity IgE 
receptors has been reported to critically impair phagocytic 
function of monocytes, a mechanism that is essential for the 
control of malaria infection33. The antigen specificity of IgE 
responses that have been associated with enhanced malaria 
morbidity remains to be determined. It is of relevance to 
RTS,S vaccination, at least in naïve subjects, since the vac-
cine targets the liver stage rather than the blood stage of the 
parasite.
3)    At Dr Luty’s suggestion we also examined levels of 
abundance of FCER1 subunits transcripts in the RTS,S 
vaccine dataset used in our analysis (Figure 4). Consist-
ently with what is observed during acute malaria infec-
tion (GSE34404)34, FCER1A and FCER1G levels were 
respectively increased and decreased one day post-RTS,S 
vaccination. However, notably, FCER1G levels remained 
significantly elevated at day 3 post-vaccination in 
non-protected individuals, while they decreased to base-
line levels in protected individuals (Figure 4D). Abundance 
of FCER1G transcript was also significantly elevated in a 
third dataset where changes were measured in patients 
during episodes of asthma exacerbation (GSE24745)35. 
Moreover, we also checked expression level of FCGR2A 
and FCGR2B in the same dataset and found that abundance 
of FCGR2A and FCGR2B were not different in subjects 
who were protected and in those who were not protected. 
Thus, taken together, these additional observations adds to 
the array of indirect evidence pointing to IgE responses as 
potential determinants of protection by the RTS,S vaccine.
Induction of IgE anti-CSP antigens after RTS,S vaccination. 
Based on those findings we contacted Drs. Dobaño and Moncunill 
from ISGlobal, Barcelona, Spain who previously measured IgG 
responses to 824 P. falciparum antigens by Luminex assay and 
protein array in Mozambican children 6 months after receiving a 
full course of RTS,S (n=291) versus comparator vaccine (n=297) 
in a Phase IIb trial. In order to further investigate the role of IgE 
responses in the context of RTS,S vaccination a novel Luminex 
assay was developed for measuring levels of total IgE, as well 
as IgE specific for CSP antigen (full length CSP, C-term, NANP 
repeat) and other blood stage vaccine candidate antigens (see meth-
ods for details). Pre-vaccinated and post-vaccinated serum sam-
ples of 23 children who received comparator vaccines (including 
11 subjects who developed clinical malaria during follow up and 
12 subjects who did not) and 44 children who received RTS,S vac-
cine were tested (22 subjects who developed clinical malaria and 
22 subjects who did not). In our interpretation of the results of 
this study we consider that the individuals who developed infec-
tion during the follow up period were not protected (noted as “not 
protected”), while those who did not develop infection were either 
protected or not exposed (noted as “protected/non-exposed”).
Induction of IgE anti-CSP antigens after RTS,S vaccination. The 
results obtained demonstrate, first that RTS,S vaccination elicits a 
robust IgE response (Figure 5A). Indeed, levels of CSP-specific 
IgE were significantly higher in serum samples post-vaccination as 
compared to pre-vaccination, these results were confirmed when 
different regions of CSP (C-Term and NANP) and HBsAg were 
tested.
Second, post-vaccination levels of CSP antigen-specific IgE 
were not different between the non-protected (NP) and protected 
(P)/non-exposed (NE) groups at the lower serum dilutions tested 
(Figure 5A), and were significantly lower in the non-protected group 
compared to the protected/NE at higher dilutions (Figure 5B). This 
finding does not support our initial hypothesis, which putatively 
attributed the suppressed interferon signatures observed in non- 
protected individuals to higher levels of antigen-specific IgE. 
However, the fact that the subjects in the first study were malaria-
naïve adults, and in the second were pre-exposed children does 
not allow drawing definitive conclusions on this point yet.
Indeed, thirdly, it was observed that levels of anti-CSP IgE in 
pre-vaccination samples of the non-protected group tended to be 
higher than in the protected/ NE group (Figure 5A). A similar, 
and more marked trend was observed when measuring total IgE 
in both comparator and RTS,S vaccines groups (Supplementary 
Figure 2). However, notably, levels of IgE specific for MSP2, MSP3 
and EXP1 antigens, which are not part of RTS,S vaccine, were sig-
nificantly elevated in the non-protected group when compared to the 
protected/NE group in both pre- and post- RTS,S vaccination time 
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Figure  4. Abundance of  FCER1A and FCER1G  transcripts  in whole  blood  samples of RTS,S  vaccinated  subjects,  acute malaria 
infection and asthma patients. mRNA expression levels for FCER1A and FCER1G were measured by microarrays in whole blood obtained 
following RTS,S vaccination (GSE18323), or in patients with acute malaria infection (GSE34404) or asthma (GSE2475). GSE18323: Samples 
were collected at study entry, the day of third vaccination (Day 0), 24 (Day 1) and 72 (Day 3) hours post the third vaccination and two weeks 
(Day14) post the third vaccination. Of 39 vaccine recipients, 13 were protected (blue) and 26 were not protected (orange)15. https://www.ncbi.
nlm.nih.gov/geo/query/acc.cgi?acc=GSE18323. GSE34404: Whole blood gene expression profiles and genotypes from 155 West-African 
children including 94 cases (Rapid Diagnostic (RD) Positive) undergoing the symptomatic phase of blood-stage P. falciparum infection and 
61 age-matched controls (RD negative)34. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE34404. GSE24745: Asthmatic subjects 
(20–60 years of age, with stable, mild allergic asthma, n=17) underwent allergen inhalation challenges. All subjects had an early asthmatic 
response of ≥ 20% fall in FEV1; most had a late phase response of ≥ 15% fall in FEV1. Blood was collected immediately prior to, and two hours 
after allergen challenge35. https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE24745.
points (Figure 5C). Given that such differences were not observed 
in the comparator vaccine group we analyzed separately subjects 
from cohort 1 (low/moderate transmission, passive case detection) 
and from cohort 2 (high transmission, active case detection). Levels 
of IgE were significantly higher in non-protected groups of both 
comparator vaccine control and RTS,S vaccine (Figure 6 / and 
Supplementary figure 3.
Altogether these observations suggest that IgE specific antibodies 
are also produced during natural exposure, and that elevated levels 
of IgE specific for blood stage antigens may be associated with poor 
clinical outcomes upon parasite re-exposure, regardless of RTS,S 
vaccination status.
Conclusions
Gaining an understanding of immunological mechanisms that con-
fer protection via immunization with the RTS,S malaria vaccine, 
or conversely that prevent it, can help address decisively the global 
health challenges caused by malaria infection. In this report we iden-
tify an interferon blood transcriptional signature correlating with 
protection following subsequent infectious challenge. As pointed 
out in the comments posted by Dr Luty, one of the reviewers, this 
finding is consistent with immunological profiling results obtained 
by the team who carried out the trial and who reported higher fre-
quencies of IFN-γ-producing T cells in individuals protected from 
an experimental challenge22,29. However, the mechanism of induc-
tion of the transcriptional interferon signature that was observed 
and the nature of the leukocyte population(s) carrying this signature 
remains to be elucidated in the context of RTS,S vaccination.
Furthermore, we tentatively attributed the peculiar decrease in 
abundance of interferon-inducible transcripts observed at days 
3 and 14 following administration of the third dose of the vac-
cine to the possible elicitation of an IgE response in a subset of 
individuals that failed to be protected by vaccination. This hypoth-
esis was corroborated indirectly by the sustained increase in lev-
els of FCER1G transcripts observed in response to vaccination 
in the non-protected group. As we sought to gather additional 
evidence we turned to collaborators, Drs Dobaño and Moncunill, 
in order to test IgE responses in vaccinated pediatric sub-
jects from Mozambique. Notable differences from the original 
study included age, ethnicity and, importantly, prior exposure 
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Figure 5. Detection of antigen-specific IgE in serum samples of children who received the RTS,S vaccine or comparator vaccines. 
IgE levels are shown for 23 children who received the comparator vaccines (11 non-protected (NP) and 12 protected(P)/Non-exposed (NE) 
subjects) and 44 children who received the RTS,S vaccine (22 non-protected and 22 protected/NT subjects). Blood samples were collected 
from children at baseline before receiving the vaccine (pre-vaccination) and 1 month after the 3rd dose of vaccination (post-vaccination). The 
children who developed malaria infection during follow up were classified in the “Non-protected” group and those who did not, were classified 
in the “Protected/NE” group. A) comparison of levels of CSP-, CTerm-, NANP-specific IgE (dilution 1:30), and MSP2-, MSP3-, EXP1-specific 
IgE (dilution 1: 2,430) in serum samples of comparator vaccine control or RTS,S vaccine groups. Red, green and brown boxes identify the 
samples that were over the higher limit of quantification. B) Antigen-specific IgE in serum samples of RTS,S vaccinated group identified by 
the red, green and brown boxes in panel A which were re-run at a higher dilution (1: 21,870). C) Comparison of levels of MSP2-, MSP3- and 
EXP1-specific IgE in serum samples of comparator vaccine control or RTS,S vaccine; blue represented “Protected/NE” and orange represented 
“Non-protected”. The results represent means ± standard errors (SE). Statistical significance was determined using Wilcoxon signed-rank 
test or Mann Whitney test; ns, not significant, * p < 0.05, ** p < 0.01, *** p < 0.001 and **** p < 0.0001. The horizontal lines indicate mean ± 
standard errors (SE).
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Figure 6. Comparison of specific IgE in serum samples of children from cohort 1 and cohort 2 who received the RTS,S vaccine or 
comparator vaccines (1:270 dillution). 23 children received comparator vaccines (11 non-protected and 12 protected(P)/Non-exposed (NE) 
subjects) and 44 children received the RTS,S vaccine (22 non-protected and 22 protected/NE subjects). Blood samples were collected from 
children at baseline before receiving the vaccine (pre-vaccination) and 1 month after the 3rd vaccine dose (post-vaccination). The children 
who developed malaria infection were classified in the “Non-protected” group and those who did not were in the “Protected/NE” group. The 
samples were diluted at 1:270 for the IgE assay. A) Comparison of CSP-, MSP2-, MSP3- and EXP1-specific IgE levels in serum samples of 
comparator vaccine control or RTS,S vaccine groups from cohort 1 (low transmission area, passive case detection). B) Comparison of levels 
of CSP-, MSP2-, MSP3- and EXP1-specific IgE levels in serum samples of comparator vaccine control or RTS,S vaccine groups from cohort 
2 (high transmission area, active case detection). Blue represents “Protected/NE” and orange represented “Non-protected”. The results 
represent means ± standard errors (SE). Statistical significance was determined using Wilcoxon signed-rank test or Mann Whitney test; ns, 
not significant * p < 0.05, ** p < 0.01 and **** p < 0.0001. The horizontal lines indicate mean ± standard errors (SE).
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to the pathogen since the subjects live in regions where malaria 
is endemic. Despite the pre-immune status, as was previously 
reported with IgGs36, we found the RTS,S vaccine to be a potent 
inducer of IgE responses. We also found that level of CSP- 
specific IgEs post-vaccination were either not different or lower in 
non-protected individuals, which goes against our initial hypoth-
esis putatively implicating elevated IgE levels for the suppressed 
interferon signatures observed on days 3 and 14 post-vaccination. 
However, given significant differences in the respective settings 
for the trials in which transcriptional and serological profiles were 
obtained it is not yet possible to conclude decisively on this point. 
Indeed, as one of the reviewers, Dr Luty, pointed out in his com-
ments: “the vaccine’s capacity for induction of immunological 
responses in malaria non-exposed adults in North America may 
be quite far removed from its capacity to induce responses in 
sub-Saharan African newborns or infants, many of whom could 
have had some exposure to the pathogen or its products already 
either in utero or in early life”29. The potential role played by prior 
P. falciparum exposure is evidenced by the fact that levels of MSP-
specific IgE at pre-vaccination baseline was significantly higher in 
non-protected individuals, compared to protected individuals. A 
similar trend was observed for CSP-specific IgEs and total IgEs but 
differences were not significant. Notably, the differences were also 
more marked in the first cohort of subjects from low to moderate 
transmission areas for which infections were monitored passively 
(based on occurrence of clinical symptoms). The observation that 
IgE levels and specificity resulting from natural exposure to para-
site in endemic areas was associated with development of disease 
may be a finding of potential clinical significance that remains to be 
replicated in independent studies. Furthermore, as pointed out by 
Dr Milon in her comments, extending the investigation to include 
profiling of IgE which are specific for antigen present in the saliva 
of the vector is also warranted37.
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Supplementary material
Supplementary figure 1
Click here to access the data.
Mapping of the immunoproteasome geneset to the blood modular repertoire framework. Thirty two genes constituting the immuno-
proteasome signature described by Vahey et al., listed on the left panel, were mapped to 260 modules used in our reanalysis. The genes 
mapped to 20 different modules. Their distribution is shown on the histogram on the right. Three genes which did not map to any of the 
modules were assigned to the NA group.
Supplementary figure 2
Click here to access the data.
Detection of total IgE in serum samples of children who received the RTS,S vaccine or comparator vaccines. 23 children received 
comparator vaccines (11 non-protected and 12 protected/ Non-exposed (NE) subjects) and 44 children received the RTS,S vaccine (22 non-
protected and 22 protected subjects). Blood samples were collected from children at baseline before receiving the vaccine (pre-vaccination) 
and 1 month after 3rd dose of vaccination (post-vaccination). The children who developed clinical malaria are designated as “non-protected” 
and those who did not develop malaria were designated as protected/NE (protected or non exposed). A) comparison of total IgE in serum 
samples of comparator vaccine control group pre- and post-vaccination. B) comparison of total IgE in serum samples of RTS,S vaccine 
group pre- and post-vaccination; blue represented protected/NE subjects and orange represented non-protected subjects. The results repre-
sent means ± standard errors (SE) of median fluorescence intensity (MFI). Statistical significance was determined using Wilcoxon signed-
rank test or Mann Whitney test ns, not significant and **** p < 0.0001. The horizontal lines indicate mean ± standard errors (SE).
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Supplementary figure 3
Click here to access the data.
Comparison of specific IgE in serum samples of children from cohort 1 and cohort 2 who received the RTS,S vaccine or compa-
rator vaccines (1:2340 dillution). 23 children received comparator vaccines (11 non-protected and 12 protected(P)/Non-exposed (NE) 
subjects) and 44 children received the RTS,S vaccine (22 non-protected and 22 protected/NE subjects). Blood was collected from subjects 
at baseline, before receiving the vaccine (pre-vaccination) and 1 month after 3rd dose of vaccination (post-vaccination). The children who 
developed malaria infection were classified in the “Non-protected” group and those who did not develop infection in the “Protected/NE” 
group. The samples were diluted at 1: 2340 for the IgE assay. A) comparison of levels of CSP, MSP2, MSP3 and EXP1 antigens specific 
IgE in serum samples of comparator vaccine control or RTS,S vaccine from cohort 1. B) comparison of levels of CSP, MSP2, MSP3 and 
EXP1 antigens specific IgE in serum samples of comparator vaccine control or RTS,S vaccine from cohort 2. Blue represented “Protected/
NE” and orange represented “Non-protected”. The results represent means ± standard errors (SE). Statistical significance was determined 
using Wilcoxon signed-rank test or Mann Whitney test; ns, not significant * p < 0.05, ** p < 0.01 and **** p < 0.0001. The horizontal 
lines indicate mean ± standard errors (SE).
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Over the last 3 decades or so the development and testing of candidate vaccines for malaria has seen
numerous advances but an almost equal number of setbacks. RTS,S (aka Mosquirix) stands apart, for
now, as the only such vaccine to have advanced as far as registration. Whilst that is clearly an
achievement to be applauded, there nevertheless remain substantial gaps in our basic understanding of
the immunological mechanisms involved in the protection conferred by the vaccine. The study reported
here by Darawan Rinchai and colleagues represents an attempt to fill some of the gap in that knowledge.
The source data that Rinchai and colleagues were able to access for their analyses were derived from an
original study authored by Kester and colleagues  that comprised a comparison of outcomes, including
efficacy, of two formulations of RTS,S in different adjuvants administered to adult volunteers. Notably, that
study documented higher titres of CSP-specific IgG as well as higher frequencies of 'activated'
CSP-specific CD4  T cells and IFN-γ-producing T cells in individuals who were protected from an
experimental challenge infection with sporozoites compared to the study individuals who were not
protected. The results of an adjunct to Kester and colleagues' study were published subsequently by
Vahey and colleagues . That study documented gene expression analyses of peripheral blood
mononuclear cells isolated from the volunteers at different time-points and identified - through the use of
high-resolution geneset analysis - immunoproteasome processing of MHC peptides as predictively
distinguishing protected from unprotected individuals.
Rinchai and colleagues' analytical approach employed a 'modular' method that they had previously
developed 'in-house' and had used in other studies of vaccine-induced gene profiles. Here they used the
same approach to assess gene expression profiles in the dataset generated by Vahey and colleagues.
On that basis it would have been instructive for them to demonstrate the validity of their approach by
assessing the immunoproteasome geneset identified by Vahey and colleagues in the context of its
predictive capacity. Also, they need to justify the rationale for the module filtering procedure that
discarded any displaying changes <15%. On what basis was that threshold chosen? In passing, for
accuracy they also need to modify their repeated incorrect reference to 'blood' proteome to the correct
'peripheral blood mononuclear cell' proteome.
Rinchai and colleagues' principal finding concerning the association between upregulated expression of
an 'interferon module' response and protection conferred by RTS,S appears to be consistent with the
enhanced T cell responses associated with protection reported by Kester and colleagues in the same
individuals. It would also be consistent with the known role for IFN-α in enhancement of naive B cell
differentiaton . My main concern in the context of their discussion and conclusions relates to their
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 differentiaton . My main concern in the context of their discussion and conclusions relates to their
speculative interpretation for the under-expression/down-regulation of the interferon module response
they recorded both 3 & 14 days after the third RTS,S immunization in non-protected individuals. They
contend that that particular profile is most likely to be linked to an aberrant IgE rather than IgG response to
CSP. They conclude that this would result in IgE-CSP immune complex-mediated cross-linking of IgE
receptors on myeloid cells that would in turn mediate the type of down-regulation of pDC activity they
observed in the non-protected individuals. Whilst this may indeed be a plausible explanation for their
observations, it is far from being the only one, and the authors need to recognize this. Firstly, it is of
possibly central relevance here that RTS,S is a hybrid molecule comprising the CSP sequence
conjugated to a 226 amino acid stretch of hepatitis B surface antigen (HBsAg). The same portion of
HBsAg is co-expressed in unconjugated form along with the conjugate such that the purified vaccine
spontaneously forms virus-like particles. Importantly, HBsAg has been shown to inhibit IFN-α production
by pDC , implying that the 'non-malaria' component of RTS,S could thus potentially be exerting some
influence on the outcome of immunization in terma of the anti-malarial protection generated. Secondly, a
role for IgG-CSP immune complex-mediated inhibition of IFN-α production could also be envisaged
through their interaction with the inhibitory FcγRIIB receptor expressed on pDC . Thus, I feel, the authors
need to modify their article to incorporate discussion of these alternative, but not necessarily mutually
exclusive explanations for their findings. In the context of their preferred conclusion, I wonder if might it
not also be a possibility that they re-interrogate their dataset to try to identify possible changes in relevant
'modules' related to IgE/FCERI expression levels?
Finally, I also suggest strongly that they remove references to and discussion of publications that have
proposed a role for IgE in malarial morbidity. Disease manifestations due to infection with Plasmodium
  result from pathophysiological events associated with the asexual blood stage multiplicationfalciparum
phase, reference to which in the context of putative antibody responses to a component of a vaccine that
targets the pre-erythrocytic sporozoite stage are entirely erroneous in my view.
In conclusion I would say that Rinchai and colleagues' findings certainly provide some pointers to
elucidating the immunological mechanisms governing the capacity of RTS,S to induce protective
responses in some individuals but not others. I would nevertheless add the rider that the vaccine's
capacity for induction of immunological responses in malaria non-exposed adults in North America may
be quite far removed from its capacity to induce responses in sub-Saharan African newborns or infants,
many of whom could have had some exposure to the pathogen or its products already either  or inin utero 
early life. Such exposures could plausibly modulate their capacity to respond to vaccines in general and
to a malaria vaccine in particular.
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We would like to thank the reviewers for their time and constructive feedback. In this revised
version, we have added a new result section and figure showing FCER1 transcript profiles in
vaccinated individuals, as well as newly generated IgE profiling data measured in plasma samples
of children from malaria endemic areas who received the RTS,S vaccine or a comparator vaccine.
We have included below our response to the points that were raised in the review.
Approved with Reservations
...
Rinchai and colleagues' analytical approach employed a 'modular' method that they had previously
developed 'in-house' and had used in other studies of vaccine-induced gene profiles. Here they
used the same approach to assess gene expression profiles in the dataset generated by Vahey
and colleagues. On that basis it would have been instructive for them to demonstrate the validity of
their approach by assessing the immunoproteasome geneset identified by Vahey and colleagues
in the context of its predictive capacity.
 Authors: Indeed, this is an important point. We assessed the overlap of the proteasome signature
reported by Vahey et al. with our modular genesets. Six genes overlapped with module M5.13 and
three with module M5.4 (Supplementary Figure 1). However, neither M5.13 nor M5.4 were
identified as being associated with protection, or lack of protection following RTS,S vaccination.
 
We added the paragraph below in the result section “Decreased interferon module response at
and show results in supplementary figure 1days 3 and 14 correlate with lack of protection” 
 
“Notably, we found that the genes constitutive of M1.2, M3.4 and M5.12 do not overlap with the
day 14 immunoproteasome signature (32 genes) described by Vahey et al (Supplementary figure
1). All but three of the 32 genes mapped to the modules constituting our repertoire. Six
genes mapped to module M5.13 and three to module M5.4, the remaining 23 genes mapped to 18
other modules. However, none of the genes mapped to either of the three interferon modules
identified as associated with protection by RTS,S vaccine at Day 1, 3 or 14 after the third
vaccination. Notably, IFNG, which was part of the 32 gene signature is among the genes
constituting M3.6, which is associated with NK cells/Cytotoxic activity.”  
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Also, they need to justify the rationale for the module filtering procedure that discarded any
displaying changes <15%. On what basis was that threshold chosen?
 
Authors: We have added the sentence below in the manuscript to clarify this point;
 
“This arbitrary cutoff is set at three times the false discovery rate used for multiple testing
correction (5%), which allows effective filtering of false positive results.”
 
 
In passing, for accuracy they also need to modify their repeated incorrect reference to 'blood'
proteome to the correct 'peripheral blood mononuclear cell' proteome.
 
Authors: The manuscript was edited accordingly and reference now being made to “Peripheral
blood mononuclear cell transcriptome….” Throughout.
Rinchai and colleagues' principal finding concerning the association between upregulated
expression of an 'interferon module' response and protection conferred by RTS,S appears to be
consistent with the enhanced T cell responses associated with protection reported by Kester and
colleagues in the same individuals. It would also be consistent with the known role for IFN-α in
enhancement of naive B cell differentiaton . My main concern in the context of their discussion and
conclusions relates to their speculative interpretation for the under-expression/down-regulation of
the interferon module response they recorded both 3 & 14 days after the third RTS,S immunization
in non-protected individuals. They contend that that particular profile is most likely to be linked to
an aberrant IgE rather than IgG response to CSP. They conclude that this would result in IgE-CSP
immune complex-mediated cross-linking of IgE receptors on myeloid cells that would in turn
mediate the type of down-regulation of pDC activity they observed in the non-protected individuals.
Whilst this may indeed be a plausible explanation for their observations, it is far from being the only
one, and the authors need to recognize this. Firstly, it is of possibly central relevance here that
RTS,S is a hybrid molecule comprising the CSP sequence conjugated to a 226 amino acid stretch
of hepatitis B surface antigen (HBsAg). The same portion of HBsAg is co-expressed in
unconjugated form along with the conjugate such that the purified vaccine spontaneously forms
virus-like particles. Importantly,  ,HBsAg has been shown to inhibit IFN-α production by pDC
implying that the 'non-malaria' component of RTS,S could thus potentially be exerting some
influence on the outcome of immunization in terma of the anti-malarial protection generated.
Secondly, a role for IgG-CSP immune complex-mediated inhibition of IFN-α production could also
be envisaged through their interaction with the inhibitory FcγRIIB receptor expressed on pDC .
Thus, I feel, the authors need to modify their article to incorporate discussion of these alternative,
but not necessarily mutually exclusive explanations for their findings. In the context of their
preferred conclusion, I wonder if might it not also be a possibility that they re-interrogate their
dataset to try to identify possible changes in relevant 'modules' related to IgE/FCERI expression
levels?
 Authors: These comments have contributed significantly to the discussion and interpretation of
the IgE profiling data presented in this revised manuscript: 
With regards to the first point made in the comment above: 
“An alternative explanation is advanced by Dr Luty in his comments, who mentions the potential
relevance of the use of a 226 amino acid stretch of HBsAg as a conjugate for the CSP antigen in
the RTS,S vaccine. Indeed this molecule has also been shown to inhibit Toll-like Receptor
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 the RTS,S vaccine. Indeed this molecule has also been shown to inhibit Toll-like Receptor
(TLR)9-mediated IFN-α production by pDC [Shi B., et al., PLoS One. 2012], and “could thus
potentially be exerting some influence on the outcome of immunization in term of the anti-malarial
protection generated” [Luty AJF., Referee report., F1000Research 2015, 4:919]. This is indeed
another possibility, which warrants testing of the inhibitory capacity of the protein fragment used in
RTS,S vaccine formulation. Furthermore the cell populations and signaling pathways involved in
elicitation and modulation of interferon responses by RTS,S vaccine would also need to be
investigated. It was found for instance that, rather unexpectedly, the induction of interferon
response by the trivalent influenza vaccine is mediated by immune-complexes rather than TLR
engagement [O'Gorman WE., et al., Vaccine. 2014].”
 
With regards to the second point made in the comment above: 
 
“At Dr Luty’s suggestion we also examined levels of abundance of FCER1 subunits transcripts in
the RTS,S vaccine dataset used in our analysis ( ). Consistently with what is observedFigure 4
during acute malaria infection (GSE34404) [22949651], FCER1A and FCER1G levels were
respectively increased and decreased one day post-RTS,S vaccination. However, notably,
FCER1G levels remained significantly elevated at day 3 post-vaccination in non-protected
individuals, while they decreased to baseline levels in protected individuals ( ).Figure 4D
Abundance of FCER1G transcript was also significantly elevated in a third dataset where changes
were measured in patients during episodes of asthma exacerbation (GSE24745) [22316092].
Moreover, we also checked expression level of FCGR2A and FCGR2B in the same dataset and
found that abundance of FCGR2A and FCGR2B were not different in subjects who were protected
and in those who were not protected.”  
 
 
Finally, I also suggest strongly that they remove references to and discussion of publications that
have proposed a role for IgE in malarial morbidity. Disease manifestations due to infection with 
 result from pathophysiological events associated with the asexual bloodPlasmodium falciparum
stage multiplication phase, reference to which in the context of putative antibody responses to a
component of a vaccine that targets the pre-erythrocytic sporozoite stage are entirely erroneous in
my view.
 
Authors: The IgE profiling results that have been newly generated illustrate the point made by Dr
Luty. It shows a weak association with elevated baseline levels of CSP-specific IgEs and
subsequent malaria morbidity, but a much stronger association with MSP-specific IgEs. These
findings make the point raised and citations in question all the more relevant. The discussion points
have been modified accordingly: 
 
“Further evidence pointing to the influence of IgE responses comes from the literature and from
results of our preliminary investigation reported below showing a dependence on both stages and
antigen specificity of IgE on outcomes of malaria infection in children from endemic areas.
Perlmann et al. identified IgE as a pathogenic factor in malaria, with immune complexes
contributing to excess TNF induction in PBMC in vitro . Mice deficient for the high affinity IgE
receptor have shown increased resistance to blood-stage of parasite infection, specifically
implicating FCER1 expressing neutrophils as pathogenic mediators . A more recent study has
established a link between asthma and atopic dermatitis and delayed development of clinical
immunity to P. falciparum . Notably, in addition to shifting cytokine balance by promoting IL-10
and TNF production, engagement of high affinity IgE receptors has been reported to critically
impair phagocytic function of monocytes, a mechanism that is essential for the control of malaria
26
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 impair phagocytic function of monocytes, a mechanism that is essential for the control of malaria
infection . The antigen specificity of IgE responses that have been associated with enhanced
malaria morbidity remains to be determined. It is of relevance to RTS,S vaccination, at least in
naïve subjects, since the vaccine targets the liver stage rather than the blood stage of the parasite.”
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It is a pleasure to provide my comments and highlight some issues in your well-conceived and
well-conducted re-analysis of dataset generated and assembled by Vahey  ; this  latter study waset al
conducted to investigate changes in transcript abundance in Peripheral Blood Mononuclear Cells/PBMCs
prepared from blood sampled from human volunteers who were recipients of  three doses of the
recombinant  RTS,S vaccine containing a protein named Circum Sporozoite Protein/  CSP. Of note the
CSP is displayed at the surface of by the human- invasive 3D7  developmentalPlasmodium falciparum 
stage population named the invasive sporozoite population.
  
The invasive properties of sporozoite population
reflect maturation within the salivary glands of the blood-feeding  /Anopheles stephensi A.s
 
and is transmitted when these blood-feeding anopheline mosquitos are
1. either probing the skin.
2. or sampling their blood meals,
 
whether it is one or the other process it is coupled to  delivery  of   both saliva   A. stephensi saliva 
molecules and sporozoites.
Your re-analysis did allow generating interesting data sets
with the identification of an interferon transcriptional signature at day 1 post-vaccination, correlating
with protection,
 
as well as the identification of  distinct interferon transcriptional signatures at days 3 and 14
post-vaccination correlating, at these  time points,  with  reduced or lack of protection of study
subjects from subsequent challenges with sporozoites delivered by insectarium
reared-blood-feeding  hosting mature sporozoites in their salivary glandsAnopheles 
When concluding your re-analysis and the putative model accounting for the contrasted interferon
signatures monitored at day 1 and days 3 and 14 post RTS,S vaccination, please could you also consider
another biologically sound variable , namely the  potentially contrasted ratio profile of the Anopheles
saliva molecules-binding IgE/IgG: indeed you are aware that infants and adults who share durably the
habitats of blood feeding    spp are more frequently exposed to   females that do notAnopheles Anopheles
act as   sporozoite vectors but that deliver saliva in the dermis a site where many salivaPlasmodium
derived agonists are rapidly sensed by immune sensors the T cell receptors and the membrane Ig
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 derived agonists are rapidly sensed by immune sensors the T cell receptors and the membrane Ig
receptors included; such features are reflected by the ability to detect saliva –reactive T cells and
saliva-reactive Ig molecules in the blood at very early times points post either skin probing or blood
sampling by blood feeding insects.
 
Please note that blood- feeding  does not transmit malaria – the latter term is expected toAnopheles 
depict only the symptoms that occur over the asexual   intra- erythrocytic developmentalP. falciparum
program : the blood feeding Anopheles delivers saliva while transmitting  sporozoites that will further
reach the hepatocytes where proceeds  the generation of    merozoites that are invasive forP. falciparum
erythrocytes .
 
Please could you review the Fig 3 legend:
"Figure 3. Proposed immunological mechanism determining protection – or lack thereof – in
the RTS,S vaccine.adult human individuals to whom was inoculated 
Our model infers that the interferon signatures observed on days 1, 3 and 14 post-vaccination correlating
with outcome of the processes that deploy post the co-delivery of Anopheles saliva and P. falciparum
, are the result of engagement of  by immune complexes.sporozoites Fc receptors
According to our model no interferon signatures should be observed following administration of the first
vaccine dose of the , in absence of pre-existing immuneCSP- containing RTS,S vaccine
effectors/regulators reactive to P. falciparum Circum Sporozoite Protein/CSP.
The injection of the first two doses of vaccines should elicit a humoral response, which in non-protected
individuals is dominated by  rather than IgG.  immune complexes should formCSP- binding IgE CSP- Ig-
when the third vaccine dose is administered.
The transient interferon response elicited in individuals who develop a protective response and that we
observed at Day 1 could be mediated  engagement of the by IgG-CSP immune complexes as by FcγR 
has been described earlier in the context of influenza vaccination) .
Our model predicts that IgE-CSP complexes form in non-protected individuals and cross-link the high
affinity at . FCER1 engagement would in turnIgE receptor the surface of cells of  the myeloid lineage
mediate  of IFN-inducible (IFI) transcripts that is observed on days 3 and 14.reduction in levels
This of constitutive levels of IFN inducible in the non-protected group would be reduction transcripts 
countered at least partially on Day 1 by residual IgG-IC response in subjects displaying mixed IgE/IgG
humoral responses.
If this is indeed the case the levels of M1.2 reduction on Day 1 in individuals displaying CSP-binding IgE
should be inversely correlated with levels of CSP-specific IgG."
Many thanks for your attention
 No competing interests were disclosed.Competing Interests:
I have read this submission. I believe that I have an appropriate level of expertise to confirm that
it is of an acceptable scientific standard.
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 Author Response 22 Jun 2017
, Sidra Medical and Research Center, QatarDamien Chaussabel
We thank you very much for your time and valuable comments.
All your edits have been incorporated in the legend of Figure 3. 
At the end of the conclusion we added the following sentence to reflect the suggestion that you
have made, which is made all the more relevant by the data that we have generated and are now
presenting in the second version of this manuscript.
"Furthermore, as pointed out by Dr Milon in her comments, extending the investigation to include
profiling of IgE which are specific for antigen present in the saliva of the vector is also warranted
[REF]."  
REF: Milon G. Referee Report For: Blood Interferon Signatures Putatively Link Lack of Protection
Conferred by the RTS,S Recombinant Malaria Vaccine to an Antigen-specific IgE Response
 [version 1; referees: 1 approved, 1 approved with reservations]. F1000Research 2015, 4:919 
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